W
NKTR icon

Wealthfront’s Nektar Therapeutics NKTR Stock Holding History

Wealthfront’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$703K Sell
769
-62
-7% -$52.9K 0.01% 327
2018
Q2 		$608K Buy
831
+583
+235% +$672K 0.01% 338
2018
Q1 		$395K Buy
+248
New +$320K ﹤0.01% 402
2015
Q4 		– Sell
-40
Closed -$7K – 782
2015
Q3 		$7K Buy
40
+38
+1,900% +$6.72K ﹤0.01% 1050
2015
Q2 		$0 Buy
+2
New +$344 ﹤0.01% 1357

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Wealthfront's NKTR Position: Q3 2018 in Review

Wealthfront reduced its Nektar Therapeutics (NKTR) stake by 7.5% in Q3 2018, selling an estimated $52.9K and leaving 769 shares worth $703K. The position accounts for 0.01% of the portfolio, ranked #327.

Wealthfront first reported a position in NKTR in Q2 2015 and has held it in 5 quarters since. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • Wealthfront held 769 shares of Nektar Therapeutics worth $703K as of Q3 2018.
  • Wealthfront sold 62 Nektar Therapeutics shares in Q3 2018, an estimated $52.9K.
  • Nektar Therapeutics made up 0.01% of Wealthfront's portfolio in Q3 2018, its #327 holding.
  • Wealthfront first reported a position in Nektar Therapeutics in Q2 2015 and has held it in 5 quarters since.
  • 389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Wealthfront's 13F filing for Q3 2018, filed 13 Nov 2018.